LIVE WEBINAR
Share:

Using SPC and Process Data to Support Quality, Stability, and Manufacturing Decisions

  • Date
    09 September 2026
  • 11.00 AM Eastern Time (US/Canada)
    03.00 PM GMT

Course is now LIVE. Click below to join the session.

This course helps teams use statistical evidence to support process control, sampling, validation, trending, and manufacturing decisions while identifying meaningful variation before it develops into larger quality or operational concerns. 

/* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } /* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } .accordion-header::after { content: "◯"; font-size: 18px; transition: transform 0.25s ease; } .accordion-item.active .accordion-header::after { transform: rotate(90deg); }
REGISTRATION OPTIONS

Live session Plus
Complimentary 30 Days Streaming access

$290  |  One participant (viewer)

$390  |  Team (2 - 5 participants)

$490 |  Team (6 - 10 participants)

REGISTER FOR THE COURSE

US $290 per learner

30-Days Unlimited Streaming Access

/* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } /* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } .accordion-header::after { content: "◯"; font-size: 18px; transition: transform 0.25s ease; } .accordion-item.active .accordion-header::after { transform: rotate(90deg); }

REGISTER FOR THE COURSE

To Get 30-Day Access to ONLY this Course 

US $290 per learner
  • This course is Included in Subscription Pack
Subscription include access to entire Learning Library
/* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } /* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } .accordion-header::after { content: "◯"; font-size: 18px; transition: transform 0.25s ease; } .accordion-item.active .accordion-header::after { transform: rotate(90deg); }
  • Faculty
    John E. Lincoln
  • Duration
    90 Minutes
  • Course ID
    TF3755
  • Live Q&A +
    Post-live Continued Learning
  • Presentation Handout
    & Templates
  • Assessment
    & Certification Included

 

Why take this course?

Statistical Process Control (SPC) provides a structured way to monitor process behavior, distinguish meaningful change from routine variation, and support production and quality decisions across CGMP manufacturing. FDA expectations increasingly emphasize appropriate statistical techniques for establishing, controlling, and verifying process capability, product characteristics, sampling plans, validation evidence, and recurring quality trends. Used effectively, SPC can strengthen production control while reducing avoidable rework and scrap. 


This webinar examines how SPC, Six Sigma concepts, control charts, capability measures, sampling justification, and trend analysis can be applied to regulated manufacturing and laboratory operations. Participants will consider common cause versus special cause variation, equipment monitoring, verification and validation studies, and the use of nonconformance, complaint, and CAPA data as early indicators of process change. The focus is on using process data to support consistent quality, stability, and manufacturing decisions under CGMP expectations. 

Recognize Meaningful Process Signals Earlier 

Build the ability to distinguish routine process variation from signals that warrant closer evaluation. Understanding common cause and special cause variation, control charts, capability measures, and early warning indicators helps teams make better-supported decisions before emerging process changes affect product conformity, validation status, or ongoing manufacturing control. 

Use Statistical Evidence to Support Quality Decisions 

Strengthen how statistical evidence is used to justify sampling plans, verification and validation studies, and recurring quality reviews. Trending nonconformances, complaints, CAPAs, and equipment performance gives quality and manufacturing teams a clearer basis for deciding when additional investigation, corrective action, or continued monitoring is appropriate. 

Key Areas Covered

  • SPC and Six Sigma concepts for regulated manufacturing 
  • Common cause versus special cause process variation 
  • Control charts, GR&R, and Cpk interpretation 
  • Sampling plan and sample size justification 
  • Verification and validation using statistical evidence 
  • Equipment performance monitoring across production and laboratories 
  • Trending nonconformances, complaints, and CAPA data 
  • FDA QMSR and 21 CFR 211 statistical control expectations 

Who Must Attend

  • Quality Assurance Departments
  • Quality Control Departments
  • Research and Development Departments
  • Regulatory Affairs Departments
  • Manufacturing Departments
  • Engineering Departments
  • Operations Departments
  • Production Departments
  • Validation Departments
  • Marketing Departments
  • Documentation Departments
John E. Lincoln
COURSE DIRECTOR

John E. Lincoln

John E. Lincoln has over 40 years of experience in FDA-regulated industries, including quality assurance, regulatory affairs, process and product validation, QMS remediation, and manufacturing engineering. His background across regulated manufacturing and validation supports the practical application of SPC, process capability, statistical controls, and production data to quality and manufacturing decisions. 

If you would like to request a Proforma invoice to sign up for this course. please click here

Commonly Asked Questions About This Subject

The following questions address practical regulatory, compliance, validation, quality, operational, and inspection-related considerations commonly associated with this subject.

When should a statistically significant process change trigger investigation if all product results remain within specification? 

A statistically meaningful shift can warrant investigation before any specification failure occurs. Waiting for an OOS result can defeat much of the value of process monitoring because the process may have been changing for several batches before product acceptance criteria were threatened. 


The decision should consider the magnitude and persistence of the shift, process capability, relationship of the affected parameter to product quality, historical behavior, and whether an assignable cause can reasonably be identified. A single unusual point and a sustained directional movement should not automatically receive the same response. 


Inspection friction develops when control charts or trend reports clearly show changing behavior but there is no documented assessment because every batch passed release testing. That suggests the statistical system was being maintained without influencing manufacturing decisions. 


A strong record shows that the signal was recognized, technically assessed, and either escalated or closed with a documented rationale based on process knowledge and product risk. 

How should teams respond when a process is statistically stable but its capability is too close to the specification limits? 

Stable performance does not provide much comfort when normal process variation leaves insufficient room between routine operation and the specification limits. A process can behave predictably while still carrying an unacceptable probability of producing nonconforming output. 


This situation deserves management attention before failures begin appearing. The practical question is whether the observed capability provides enough margin for normal sources of variation such as raw material differences, equipment wear, environmental conditions, operators, or measurement uncertainty. 


What becomes difficult to defend is repeated acceptance of marginal capability simply because recent batches passed. Historical conformance can support the assessment, but it does not explain why future performance should remain acceptable when the available operating margin is already narrow. 


A sound decision documents the capability assessment, product risk, known sources of variation, and any monitoring or improvement actions considered necessary. That demonstrates active process control rather than dependence on finished-product testing to detect deterioration. 

What makes a statistical sampling plan difficult to defend during an FDA inspection? 

A sampling plan becomes vulnerable when the sample size was inherited, copied from a procedure, or selected for convenience without a documented connection to the decision being made. An inspector can quickly move from asking what the sample size is to asking why that number provides sufficient evidence. 


The justification should reflect the purpose of sampling, expected variability, severity of an incorrect decision, process knowledge, and the confidence required from the resulting data. Sampling twenty units because "that is our standard practice" carries considerably less weight than a rationale tied to the specific process and risk. 


Problems also arise when the same sampling approach is used for routine acceptance, validation, investigations, and process changes even though those activities answer different questions. 


The strongest documentation shows that the organization understood what conclusion the sample was expected to support and selected an approach capable of supporting that conclusion. Statistical calculations matter, but their assumptions and intended use need to make operational sense. 

How should quality teams handle repeated minor trends that never individually cross established statistical or procedural limits? 

Repeated minor signals should be evaluated collectively when they begin forming a pattern. One of the easiest process problems to miss is a gradual deterioration composed entirely of observations that remain individually acceptable. 


This occurs when each complaint category, minor nonconformance, adjustment, yield change, or process fluctuation is reviewed against its own trigger and closed because no threshold was exceeded. Months later, the combined data may show that process behavior had been changing well before a significant event occurred. 


Inspection questions become uncomfortable when the information was available but fragmented across reports or quality systems and nobody evaluated the cumulative signal. Established alert limits should therefore support judgment rather than prevent it. 

Periodic cross-functional review can determine whether apparently unrelated indicators share a product, equipment, material, process step, supplier, or time-based relationship. Detecting that relationship early provides stronger evidence of process understanding and often prevents substantially more expensive investigations and corrective actions later. 

Your TalkFDA Webinar Experience

When you reserve your seat, everything is organized for you — from access to certification from one place.

1. Confirmation

You receive a confirmation email and your course appears instantly in your TalkFDA dashboard.

2. Your Course Hub
Your TalkFDA course page becomes your central hub where you can join the session, access materials, and manage your learning.

3. Join the Live Training
At the scheduled time, click Join Session and you’ll be connected to the live Webex session with the instructor.

4. Watch Again Anytime
After the session, the playback becomes available on the same course page so you can revisit important sections.
5. Earn Your Certificate
Complete the course and your certificate is unlocked automatically in your learning history.

Everything related to your webinar: access, materials, playback, and certification — lives in one place.
Simple. Organized. Professional.
Go ahead and reserve your seat with confidence.

Built on 20+ years of global regulatory training experience across FDA, EMA, MHRA, and ICH frameworks.
Trusted by professionals across 80+ countries.

Testimonials

This is an upcoming session. Feedback below reflects experiences from similar programs delivered by our expert faculty.

“Session was easy to follow even for non-core team members. That helped.”
- Production Officer
“Good balance. Not too basic, not too deep. Worked well for mixed team.”
- Manager, Regulatory Affairs
“Team found it useful. Especially for aligning understanding across functions.”
- Director, Operations

Ready to Strengthen Your Team? Let’s Build Your Training Plan.

Whether you’re looking for a single onsite workshop or a multi-team training series, we’ll help you design a program that fits your goals, timelines, and operational reality.

Your team deserves the clarity.
Your organization deserves the confidence.

Upcoming Courses

Featured Courses